Higher dose radiation for locally advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that has not spread to other parts of the body.
- You must have received between 4 and 8 months of chemotherapy (not counting breaks) before joining.
- Your cancer must not have grown or spread during that chemotherapy.
- You must be 18 years or older and have a good performance status (ECOG 0-2).
- Your liver function tests must be within normal limits (unless you have high CA19-9, then specific bilirubin levels apply).
- You must not have had radiation therapy to the pancreas or nearby areas before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.
This study tests a highly focused radiation plan that uses MRI scans to adjust treatment during therapy. It’s for people with locally advanced pancreatic cancer who have already completed a set course of chemotherapy and whose cancer hasn’t grown.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
Hear when a new Stage II Pancreatic Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.